Literature DB >> 32910776

Role of Patatin-Like Phospholipase Domain-Containing 3 Gene for Hepatic Lipid Content and Insulin Resistance in Diabetes.

Oana P Zaharia1,2, Klaus Strassburger2,3, Birgit Knebel2,4, Yuliya Kupriyanova1,2, Yanislava Karusheva1,2, Martin Wolkersdorfer5, Kálmán Bódis1,2,6, Daniel F Markgraf1,2, Volker Burkart1,2, Jong-Hee Hwang1,2, Jörg Kotzka2,4, Hadi Al-Hasani2,4, Julia Szendroedi1,2,6, Michael Roden.   

Abstract

OBJECTIVE: The rs738409(G) single nucleotide polymorphism (SNP) in the patatin-like phospholipase domain-containing 3 (PNPLA3) gene associates with increased risk and progression of nonalcoholic fatty liver disease (NAFLD). As the recently described severe insulin-resistant diabetes (SIRD) cluster specifically relates to NAFLD, this study examined whether this SNP differently associates with hepatic lipid content (hepatocellular lipids [HCL]) and insulin sensitivity in recent-onset diabetes. RESEARCH DESIGN AND METHODS: A total of 917 participants in the German Diabetes Study (GDS) underwent genotyping, hyperinsulinemic-euglycemic clamps with stable isotopic tracer dilution, and MRS.
RESULTS: The G allele associated positively with HCL (β = 0.36, P < 0.01), independent of age, sex, and BMI across the whole cohort, but not in the individual clusters. Those with SIRD exhibited lowest whole-body insulin sensitivity compared with those with severe insulin-deficient (SIDD), moderate obesity-related (MOD), moderate age-related (MARD), and severe autoimmune diabetes (SAID) clusters (all P < 0.001). Interestingly, the SIRD group presented with higher prevalence of the rs738409(G) SNP compared with other clusters and the glucose-tolerant control group (P < 0.05). HCL was higher in the SIRD group (median 13.6% [1st quartile 5.8; 3rd quartile 19.1] compared with the MOD (6.4 % [2.1; 12.4], P < 0.05), MARD (3.0% [1.0; 7.9], P < 0.001), SAID (0.4% [0.0; 1.5], P < 0.001), and glucose-tolerant (0.9% [0.4; 4.9), P < 0.001) group. Although the PNPLA3 polymorphism did not directly associate with whole-body insulin sensitivity in SIRD, the G-allele carriers had higher circulating free fatty acid concentrations and greater adipose tissue insulin resistance compared with noncarriers (both P < 0.001).
CONCLUSIONS: Members of the SIRD cluster are more frequently carriers of the rs738409(G) variant. The SNP-associated adipose tissue insulin resistance and excessive lipolysis may contribute to their NAFLD.
© 2020 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32910776     DOI: 10.2337/dc20-0329

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  11 in total

1.  Clinical variable-based cluster analysis identifies novel subgroups with a distinct genetic signature, lipidomic pattern and cardio-renal risks in Asian patients with recent-onset type 2 diabetes.

Authors:  Jiexun Wang; Jian-Jun Liu; Resham L Gurung; Sylvia Liu; Janus Lee; Yiamunaa M; Keven Ang; Yi Ming Shao; Justin I-Shing Tang; Peter I Benke; Federico Torta; Markus R Wenk; Subramaniam Tavintharan; Wern Ee Tang; Chee Fang Sum; Su Chi Lim
Journal:  Diabetologia       Date:  2022-06-28       Impact factor: 10.460

2.  The additive effect of genetic and metabolic factors in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Yuya Seko; Kanji Yamaguchi; Kota Yano; Yusuke Takahashi; Kento Takeuchi; Seita Kataoka; Michihisa Moriguchi; Yoshito Itoh
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

Review 3.  The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments.

Authors:  Giovanni Targher; Kathleen E Corey; Christopher D Byrne; Michael Roden
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-05-10       Impact factor: 46.802

4.  Physical Fitness and Cardiovascular Risk Factors in Novel Diabetes Subgroups.

Authors:  Nina Saatmann; Oana-Patricia Zaharia; Klaus Strassburger; Dominik Hans Pesta; Volker Burkart; Julia Szendroedi; Norbert Gerdes; Malte Kelm; Michael Roden
Journal:  J Clin Endocrinol Metab       Date:  2022-03-24       Impact factor: 5.958

5.  A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease.

Authors:  Grazia Pennisi; Rosaria Maria Pipitone; Calogero Cammà; Antonio Craxì; Stefania Grimaudo; Salvatore Petta; Marco Enea; Antonio De Vincentis; Salvatore Battaglia; Vito Di Marco; Vincenzo Di Martino; Federica Spatola; Federica Tavaglione; Umberto Vespasiani-Gentilucci; Rossella Zito; Stefano Romeo
Journal:  Hepatol Commun       Date:  2022-02-11

6.  Cellular senescence in hepatocytes contributes to metabolic disturbances in NASH.

Authors:  Laurianne Bonnet; Ida Alexandersson; Ritesh K Baboota; Tobias Kroon; Jan Oscarsson; Ulf Smith; Jeremie Boucher
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-22       Impact factor: 6.055

7.  Oral-Gut Microbiome Analysis in Patients With Metabolic-Associated Fatty Liver Disease Having Different Tongue Image Feature.

Authors:  Chenxia Lu; Hui Zhu; Dan Zhao; Jia Zhang; Kai Yang; Yi Lv; Miao Peng; Xi Xu; Jingjing Huang; Zuoyu Shao; Mingzhong Xiao; Xiaodong Li
Journal:  Front Cell Infect Microbiol       Date:  2022-06-29       Impact factor: 6.073

Review 8.  Genetic and epigenetic factors determining NAFLD risk.

Authors:  Wenke Jonas; Annette Schürmann
Journal:  Mol Metab       Date:  2020-11-05       Impact factor: 7.422

9.  Improving insulin sensitivity, liver steatosis and fibrosis in type 2 diabetes by a food-based digital education-assisted lifestyle intervention program: a feasibility study.

Authors:  Oana P Zaharia; Yuliya Kupriyanova; Yanislava Karusheva; Daniel F Markgraf; Konstantinos Kantartzis; Andreas L Birkenfeld; Michael Trenell; Aarti Sahasranaman; Chris Cheyette; Theresa Kössler; Kálmán Bódis; Volker Burkart; Jong-Hee Hwang; Michael Roden; Julia Szendroedi; Dominik H Pesta
Journal:  Eur J Nutr       Date:  2021-04-11       Impact factor: 5.614

Review 10.  Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans.

Authors:  Kalliopi Pafili; Michael Roden
Journal:  Mol Metab       Date:  2020-11-19       Impact factor: 7.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.